Pfizer Could Seek FDA Emergency Use Authorization for COVID-19 Vaccine in October
|
By HospiMedica International staff writers Posted on 07 Sep 2020 |

Illustration
Pfizer Inc. (New York, NY, USA) should know by October if its COVID-19 vaccine candidate currently under trial works, based on which it plans to immediately seek Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
Speaking at an online press briefing organized by the International Federation of Pharmaceutical Manufacturers and Associations, Pfizer’s Chief Executive Albert Bourla said that the company would submit the candidate for approval immediately if the vaccine, developed in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany), proved to be safe and effective in the studies.
Pfizer’s recruitment for the trial is currently progressing ahead of its original plans and 23,000 patients have been enrolled until now. According to Bourla, the availability of the vaccine’s study data would be determined by the speed at which its scientists work and the severity of COVID-19 infection at its study locations in the US, Argentina and Brazil.
"Based on our calculations, we are expecting that to be in October," said Bourla.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
Speaking at an online press briefing organized by the International Federation of Pharmaceutical Manufacturers and Associations, Pfizer’s Chief Executive Albert Bourla said that the company would submit the candidate for approval immediately if the vaccine, developed in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany), proved to be safe and effective in the studies.
Pfizer’s recruitment for the trial is currently progressing ahead of its original plans and 23,000 patients have been enrolled until now. According to Bourla, the availability of the vaccine’s study data would be determined by the speed at which its scientists work and the severity of COVID-19 infection at its study locations in the US, Argentina and Brazil.
"Based on our calculations, we are expecting that to be in October," said Bourla.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read moreCritical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read moreSurgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








